{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT05942456",
      "orgStudyIdInfo": {
        "id": "PKUPH-sarcoma 16"
      },
      "organization": {
        "fullName": "Peking University People's Hospital",
        "class": "OTHER"
      },
      "briefTitle": "Soluble B7-H3 as a Biomarker for Osteosarcoma",
      "officialTitle": "An Exploratory Research of Soluble B7-H3 Expression in Peripheral Blood as a Biomarker to Monitor Therapeutic Effect of Systemic Treatment for Osteosarcoma"
    },
    "statusModule": {
      "statusVerifiedDate": "2024-05",
      "overallStatus": "RECRUITING",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2023-06-05",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2024-07-01",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2024-12-31",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2023-07-05",
      "studyFirstSubmitQcDate": "2023-07-05",
      "studyFirstPostDateStruct": {
        "date": "2023-07-12",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2024-05-11",
      "lastUpdatePostDateStruct": {
        "date": "2024-05-14",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "PRINCIPAL_INVESTIGATOR",
        "investigatorFullName": "Xie Lu",
        "investigatorTitle": "Musculoskeletal Tumor Center",
        "investigatorAffiliation": "Peking University People's Hospital"
      },
      "leadSponsor": {
        "name": "Peking University People's Hospital",
        "class": "OTHER"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "Increasing data has indicated an association between increased soluble B7-H3 (sB7-H3) levels and unfavorable prognosis in patients with malignancies. However, the level of sB7-H3 and its clinical significance in osteosarcoma are not well known. In this present study, we investigated whether sB7-H3 levels in serum could be as a biomarker for osteosarcoma treatment."
    },
    "conditionsModule": {
      "conditions": [
        "Biomarker",
        "Progression",
        "Osteosarcoma",
        "Surveillance"
      ],
      "keywords": [
        "sB7-H3",
        "osteosarcoma",
        "biomarker",
        "prognosis",
        "clinical evaluation"
      ]
    },
    "designModule": {
      "studyType": "OBSERVATIONAL",
      "patientRegistry": false,
      "designInfo": {
        "observationalModel": "COHORT",
        "timePerspective": "PROSPECTIVE"
      },
      "enrollmentInfo": {
        "count": 200,
        "type": "ESTIMATED"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "sB7-H3 of treatment-naive osteosarcoma patients",
          "description": "Before delivering neoadjuvant chemotherapy, using ELISA to test the protein expression of sB7-H3 of Peripheral Blood",
          "interventionNames": [
            "Diagnostic Test: ELISA: enzyme-linked immunosorbent assay"
          ]
        },
        {
          "label": "sB7-H3 after neoadjuvant chemotherapy for osteosarcoma patients",
          "description": "After neoadjuvant chemotherapy and before definitive surgery, using ELISA to test the protein expression of sB7-H3 of Peripheral Blood",
          "interventionNames": [
            "Diagnostic Test: ELISA: enzyme-linked immunosorbent assay"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DIAGNOSTIC_TEST",
          "name": "ELISA: enzyme-linked immunosorbent assay",
          "description": "enzyme-linked immunosorbent assay",
          "armGroupLabels": [
            "sB7-H3 after neoadjuvant chemotherapy for osteosarcoma patients",
            "sB7-H3 of treatment-naive osteosarcoma patients"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "correlation of quantity of Protein B7-H3 Expression with clinical evaluation",
          "description": "Clinical evaluation according to RECIST 1.1",
          "timeFrame": "6 months"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "correlation of quantity of Protein B7-H3 Expression with histological responses",
          "description": "Histological responses according to Huvos Grade",
          "timeFrame": "6 months"
        },
        {
          "measure": "correlation of quantity of Protein B7-H3 Expression with event-free survival",
          "description": "event-free survival calculated from starting systemic therapy to any tumor-related events for progression",
          "timeFrame": "2 years"
        },
        {
          "measure": "correlation of quantity of Protein B7-H3 Expression with overall survival",
          "description": "overall survival calculated from starting systemic therapy to death",
          "timeFrame": "5 years"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* High Grade osteosarcoma verified with pathologic diagnosis.\n* systemic treatment-naive before the first time Blood drawing.\n* ECOG 0 or 1 and all the other imagings indicate that patients could tolerate standard PKUPH-OS-02 protocol neoadjuvant chemotherapy.\n* All radiographs are complete for clinical evaluation.\n\nExclusion Criteria:\n\n* Patients who Can't tolerate blood drawing.\n* Patients without complete medical records in PKUPH system.\n* Patients who can't tolerate PKUPH-OS-02 neoadjuvant chemotherapy.\n* other conditions that investigators think are not suitable for this study.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "12 Years",
      "stdAges": [
        "CHILD",
        "ADULT",
        "OLDER_ADULT"
      ],
      "studyPopulation": "Initial treated osteosarcoma patients in PKUPH and later would recieve definitive surgery in PKUPH with complete clinical materials.",
      "samplingMethod": "NON_PROBABILITY_SAMPLE"
    },
    "contactsLocationsModule": {
      "centralContacts": [
        {
          "name": "Lu Xie, M.D.",
          "role": "CONTACT",
          "phone": "+86-13401044719",
          "email": "xie.lu@hotmail.com"
        }
      ],
      "locations": [
        {
          "facility": "Peking University People's Hospital",
          "status": "RECRUITING",
          "city": "Beijing",
          "state": "Beijing Municipality",
          "zip": "100044",
          "country": "China",
          "contacts": [
            {
              "name": "Lu Xie, M.D.",
              "role": "CONTACT",
              "phone": "+86-13401044719",
              "email": "xie.lu@hotmail.com"
            }
          ],
          "geoPoint": {
            "lat": 39.9075,
            "lon": 116.39723
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "30123093",
          "type": "BACKGROUND",
          "citation": "Wang L, Kang FB, Zhang GC, Wang J, Xie MF, Zhang YZ. Clinical significance of serum soluble B7-H3 in patients with osteosarcoma. Cancer Cell Int. 2018 Aug 13;18:115. doi: 10.1186/s12935-018-0614-z. eCollection 2018."
        },
        {
          "pmid": "36519392",
          "type": "BACKGROUND",
          "citation": "Xie L, Chen C, Liang X, Xu J, Sun X, Sun K, Yang R, Tang X, Guo W. Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy. Orthop Surg. 2023 Mar;15(3):829-838. doi: 10.1111/os.13620. Epub 2022 Dec 15."
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-20"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D018450",
          "term": "Disease Progression"
        },
        {
          "id": "D012516",
          "term": "Osteosarcoma"
        }
      ],
      "ancestors": [
        {
          "id": "D020969",
          "term": "Disease Attributes"
        },
        {
          "id": "D010335",
          "term": "Pathologic Processes"
        },
        {
          "id": "D013568",
          "term": "Pathological Conditions, Signs and Symptoms"
        },
        {
          "id": "D018213",
          "term": "Neoplasms, Bone Tissue"
        },
        {
          "id": "D009372",
          "term": "Neoplasms, Connective Tissue"
        },
        {
          "id": "D018204",
          "term": "Neoplasms, Connective and Soft Tissue"
        },
        {
          "id": "D009370",
          "term": "Neoplasms by Histologic Type"
        },
        {
          "id": "D009369",
          "term": "Neoplasms"
        },
        {
          "id": "D012509",
          "term": "Sarcoma"
        }
      ]
    }
  },
  "hasResults": false
}